Benefits
Pregnancy nausea (NVP): strongest evidence
Across multiple RCTs, ginger significantly improved pregnancy-related nausea without significantly reducing vomiting episodes. ACOG and the Society of Obstetricians and Gynaecologists of Canada include it as a first-line non-pharmacologic option; lower doses (<1,500 mg/day) appear favored. Strongest evidence base for any ginger use.
Chemotherapy and postoperative nausea
Multiple RCTs and an umbrella review confirm ginger reduces chemotherapy-induced nausea and vomiting and postoperative nausea, decreasing the need for rescue antiemetics. The effect is modest in magnitude but consistent. A reasonable adjunct to standard antiemetic regimens, not a replacement.
Osteoarthritis pain: modest effect
Meta-analysis of placebo-controlled RCTs in osteoarthritis patients found ginger modestly efficacious for pain and physical function (a small standardized effect, pain SMD about -0.30), though the ginger group was about twice as likely to discontinue (RR 2.33). Not validated head-to-head against NSAIDs at scale.
Exercise-induced muscle pain (DOMS)
RCTs show 1-2 g/day raw or heat-treated ginger reduces eccentric-exercise-induced muscle pain by roughly 25-30% and improves pain-pressure threshold. Effects are most pronounced with 1-2 weeks of pre-loading before unaccustomed exercise. Mechanism: COX-2 and prostaglandin E2 inhibition.
Blood sugar — mixed evidence
Some meta-analyses show significant fasting glucose and HbA1c reductions in type 2 diabetes, while other RCT reviews (1.2-2 g/day) found no significant effect. The benefit appears dose-dependent, with larger doses (>2 g/day) in the positive trials. Mechanism: 6-gingerol activates PPAR-γ and inhibits alpha-glucosidase.
Anti-inflammatory and lipid effects
Multiple meta-analyses show ginger supplementation reduces CRP, IL-6, TNF-α, total cholesterol, LDL, and triglycerides — particularly in metabolic syndrome and inflammatory conditions. Effects are modest but consistent. Mechanism: dual COX-1/2 and 5-LOX inhibition, plus NF-κB pathway suppression and antioxidant activity.
Digestive health and motility
Ginger accelerates gastric emptying, reduces bloating, and improves GI motility — useful for functional dyspepsia, gastroparesis, and general digestive discomfort. Mechanism: 5-HT3 and 5-HT4 receptor modulation plus cholinergic enhancement. This same prokinetic activity is mechanistically linked to the anti-nausea effect (gastric stasis is a key trigger of nausea).
Dysmenorrhea (menstrual pain)
Multiple RCTs show 750-2,000 mg ginger over the first 3 days of menstruation reduced self-reported menstrual pain in young women; some trials reported relief broadly in line with common over-the-counter pain relievers, though direct head-to-head evidence is limited. Mechanism: reduced prostaglandin synthesis. An option some people prefer to try before or alongside other measures.
Mechanism of action
Dual COX and 5-LOX inhibition
Gingerols and shogaols inhibit cyclooxygenase-1 and -2 (COX-1/2) reducing prostaglandin synthesis, and simultaneously inhibit 5-lipoxygenase (5-LOX) reducing leukotriene production. This dual-pathway activity is one proposed basis for the reductions in inflammatory markers seen in ginger trials.
5-HT3 receptor antagonism for anti-nausea effects
6-gingerol and 6-shogaol antagonize 5-HT3 (serotonin type 3) receptors in the GI tract and vomiting center — one of the serotonin receptors involved in nausea signaling. This is one proposed mechanism for the anti-nausea effects observed in ginger trials.
PPAR-γ activation and insulin sensitization
6-gingerol activates peroxisome proliferator-activated receptor gamma (PPAR-γ), improving adipocyte differentiation, adiponectin secretion, and peripheral insulin sensitivity. This nuclear receptor mechanism is one proposed basis for ginger's studied effects on blood sugar; no human body-composition outcome is claimed on this page.
Clinical trials
12 clinical trials in 1,278 pregnant women.
1,278 pregnant women
12 clinical trials in 1,278 pregnant women. Ginger significantly improved nausea symptoms (MD 1.20, 95% CI 0.56-1.84, p=0.0002, I²=0%). Vomiting reduction trended toward significance (MD 0.72, 95% CI -0.03-1.46, p=0.06). Subgroup analyses favored daily doses <1,500 mg. Foundation for current obstetric guideline inclusion.
5 placebo-controlled clinical trials, 593 OA patients (mainly knee/hip).
593 patients across pooled studies
5 placebo-controlled clinical trials, 593 OA patients (mainly knee/hip). Ginger was 'modestly efficacious' for pain (Hedges' SMD favoring ginger) and physical function. Adverse events were mild and reversible. Authors' caveat: ginger group was 2× as likely to discontinue treatment vs. placebo group, mostly due to GI tolerability. Evidence quality judged moderate (small samples, ITT issues).
10 clinical trials, 490 T2D patients.
10 clinical trials pooled
10 clinical trials, 490 T2D patients. Significant reduction in HbA1c (WMD -1.00%, 95% CI -1.56 to -0.44, p<0.001) and fasting glucose (WMD -21.24 mg/dL, p<0.001). Note: a 2024 Clinical Nutrition ESPEN review of 5 lower-dose clinical trials (1.2-2 g/day, 4-12 weeks) found NO significant effect — suggesting effect may be dose-dependent.
32 distance runners, 1.425 g/day ginger × 5 days before downhill running protocol.
32 experienced recreational distance runners.
32 distance runners, 1.425 g/day ginger × 5 days before a downhill running protocol (Wilson 2020). Ginger possibly produced a moderate reduction in running-induced muscle soreness, but effects on physical performance recovery were likely negligible. Builds on earlier work (Black 2010: 2 g/day reduced eccentric-exercise muscle pain ~25%). Effects appear strongest with 1-2 weeks of pre-exercise loading.
10 high-quality clinical trials evaluating ginger supplementation for hyperemesis gravidarum (severe pregnancy nausea).
Pregnant women with hyperemesis gravidarum (pooled across 10 trials).
10 high-quality clinical trials evaluating ginger supplementation for hyperemesis gravidarum (severe pregnancy nausea). Ginger comparable to vitamin B6 and metoclopramide for symptom relief in mild-to-moderate HG, with favorable safety profile. Severe HG generally still requires conventional antiemetic therapy.